Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
Phase 3 Trial Success: New Presbyopia Eye Drop Shows 27% Vision Improvement
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety…
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics, Inc. Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near…